Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Epigenetics in Drug Discovery

En Li's Biography



En Li, Head of Biomedical Research, Novartis Institutes for BioMedical Research Inc

Dr. En Li is Head of China Novartis Institutes for BioMedical Research based in Shanghai where he leads epigenetics research and drug discovery for cancer, liver disease, and regenerative medicine. He joined Novartis Institutes for BioMedical Research in Cambridge, Massachusetts in 2003. Prior to that, he was Associate Professor of Medicine at Harvard Medical School and member of the Cardiovascular Research Center and Cancer Research Center of Massachusetts General Hospital in Boston. He has been studying DNA methylation and histone modifications in development and disease. His current research interest includes cancer epigenetics, aging and regeneration.

En Li Image

Targeting PRC2 and Chromatin in Cancer

Tuesday, 7 March 2017 at 12:15

Add to Calendar ▼2017-03-07 12:15:002017-03-07 13:15:00Europe/LondonTargeting PRC2 and Chromatin in CancerSELECTBIOenquiries@selectbiosciences.com

This presentation will present evidence that EED226 inhibits PRC2 activity via an allosteric mechanism and provides an opportunity for treatment of PRC2-dependent cancers.


Add to Calendar ▼2017-03-06 00:00:002017-03-07 00:00:00Europe/LondonEpigenetics in Drug DiscoverySELECTBIOenquiries@selectbiosciences.com